Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
25 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Co-Diagnostics, Inc.’s names, not what it holds today.
Patents granted
25
23 utility, 2 design, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and none in 2023
Applications published
22
since 2001, to Dec 31, 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'07'08'09'10'13'14'16'17'18'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Medical technology2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
CO-DIAGNOSTICS, INC. its own name
US, as the owner printed on each patent. 6 more under the same name are not counted (printed in FR, printed in GB)
14 publishedCo-Diagnostics, Inc. its own name
named as the applicant on its applications, in US
5 publishedDNA Logix, Inc. a subsidiary
US, as the owner printed on each patent
1 publishedDNA Logix, Inc. a subsidiary
named as the applicant on its applications, in US
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Mar 25, 2025 | 12,258,620 | Allele-specific design of cooperative primers for improved nucleic acid variant genotyping | Biotechnology | CO-DIAGNOSTICS, INC. |
| Feb 6, 2024 | 11,890,489 | Treatment of neurological abnormalities using dynamic electroencephalography | Medical technology | CO-DIAGNOSTICS, INC. |
| May 31, 2022 | 11,344,745 | Treatment of neurological abnormalities using dynamic electroencephalography | Medical technology | CO-DIAGNOSTICS, INC. |
| Jul 7, 2020 | 10,704,087 | Cooperative primers, probes, and applications thereof | Biotechnology | DNA Logix, Inc. |
| Oct 9, 2018 | 10,093,966 | Cooperative primers, probes, and applications thereof | Biotechnology | DNA Logix, Inc. |
| Aug 9, 2016 | 9,410,189 | Methods of preventing non-specific reactions of nucleotide sequences | Biotechnology | CO-DIAGNOSTICS, INC. |
| Aug 26, 2014 | 8,815,514 | Detection primers for nucleic acid extension or amplification reactions | Biotechnology | CO-DIAGNOSTICS, INC. |
| Mar 18, 2014 | 8,673,569 | Primers for nucleic acid extension or amplification reactions | Biotechnology | DNA Logix, Inc. |
| Nov 5, 2013 | 8,574,856 | Methods for determining the efficiency of a therapeutic | Analysis of biological materials | CO-DIAGNOSTICS, INC. |
| Aug 6, 2013 | 8,501,669 | Systems and methods of screening biomarkers in bodily fluids | Analysis of biological materials | CO-DIAGNOSTICS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jun 6, 2024 | 2024/0182992 | METHODS AND COMPOSITIONS RELATED TO COOPERATIVE PRIMERS AND REVERSE TRANSCRIPTION | Biotechnology | Co-Diagnostics, Inc. |
| Feb 15, 2024 | 2024/0052407 | TERTIARY COOPERATIVE PRIMERS AND METHODS OF USE | Biotechnology | Co-Diagnostics, Inc. |
| Sep 7, 2023 | 2023/0279479 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACIDS USING INCREASED IFRET WITH MULTIPLE ACCEPTOR FLUOROPHORES | Biotechnology | CO-DIAGNOSTICS, INC. |
| Nov 3, 2022 | 2022/0347672 | SYSTEMS, METHODS, AND APPARATUS FOR AUTOMATED SELF-CONTAINED BIOLOGICAL ANALYSIS | Chemical engineering | CO-DIAGNOSTICS, INC. |
| May 12, 2022 | 2022/0145287 | METHODS AND COMPOSITIONS FOR NEXT GENERATION SEQUENCING (NGS) LIBRARY PREPARATION | Biotechnology | Co-Diagnostics, Inc. |
| Dec 23, 2021 | 2021/0395800 | ALLELE-SPECIFIC DESIGN OF COOPERATIVE PRIMERS FOR IMPROVED NUCLEIC ACID VARIANT GENOTYPING | Biotechnology | Co-Diagnostics, Inc. · patent 12,258,620 granted from it |
| Dec 20, 2018 | 2018/0363036 | COOPERATIVE PRIMERS, PROBES, AND APPLICATIONS THEREOF | Biotechnology | DNA Logix, Inc. · patent 10,704,087 granted from it |
| Sep 7, 2017 | 2017/0253878 | RAPID OLIGO PROBES | Biotechnology | Co-Diagnostics, Inc. |
| Aug 31, 2017 | 2017/0247752 | COOPERATIVE PRIMERS, PROBES, AND APPLICATIONS THEREOF | Biotechnology | DNA Logix, Inc. · patent 10,093,966 granted from it |
| Jun 5, 2014 | 2014/0155282 | METHODS OF DETERMINING STABILIZATION COMPOUNDS FOR PREDICTIVE BIOMARKERS | Analysis of biological materials | CO-DIAGNOSTICS, INC. |
What it applied for, 2024 to 2025: Biotechnology 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.